Log in

Bellus Health Stock Price, News & Analysis (NYSE:BLU)

$6.51
0.00 (0.00 %)
(As of 10/14/2019 08:44 AM ET)
Today's Range
$6.48
Now: $6.51
$6.80
50-Day Range N/A
52-Week Range
$1.76
Now: $6.51
$9.36
Volume40,002 shs
Average Volume38,514 shs
Market Capitalization$360.52 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
BELLUS Health Inc., a clinical-stage biopharmaceutical company, develops novel therapeutics for conditions with high unmet medical need. Its lead drug candidate includes BLU-5937, a small molecule antagonist of the P2X3 receptor for chronic cough. The company also has economic interests in various partnered development stage programs, including KIACTA for the treatment of sarcoidosis; AMO-01 for treatment of Phelan McDermid syndrome; and ALZ-801 for APOE4 homozygous Alzheimer's disease. BELLUS Health Inc. was founded in 1993 and is headquartered in Laval, Canada.

Industry, Sector and Symbol

Industry Biotechnology
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
Phone450-680-4500

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Employees10
Market Cap$360.52 million
Next Earnings Date11/13/2019 (Estimated)
OptionableNot Optionable

Receive BLU News and Ratings via Email

Sign-up to receive the latest news and ratings for BLU and its competitors with MarketBeat's FREE daily newsletter.


Bellus Health (NYSE:BLU) Frequently Asked Questions

What is Bellus Health's stock symbol?

Bellus Health trades on the New York Stock Exchange (NYSE) under the ticker symbol "BLU."

How were Bellus Health's earnings last quarter?

Bellus Health Inc. (NYSE:BLU) released its earnings results on Thursday, August, 8th. The company reported ($0.14) EPS for the quarter. The firm earned $0.01 million during the quarter. View Bellus Health's Earnings History.

When is Bellus Health's next earnings date?

Bellus Health is scheduled to release their next quarterly earnings announcement on Wednesday, November 13th 2019. View Earnings Estimates for Bellus Health.

What price target have analysts set for BLU?

5 analysts have issued 12 month target prices for Bellus Health's shares. Their forecasts range from $12.00 to $20.00. On average, they expect Bellus Health's stock price to reach $16.00 in the next year. This suggests a possible upside of 145.8% from the stock's current price. View Analyst Price Targets for Bellus Health.

What is the consensus analysts' recommendation for Bellus Health?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Bellus Health in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Bellus Health.

Has Bellus Health been receiving favorable news coverage?

Media coverage about BLU stock has been trending negative recently, according to InfoTrie Sentiment Analysis. The research group rates the sentiment of news coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Bellus Health earned a media sentiment score of -2.6 on InfoTrie's scale. They also assigned news headlines about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the stock's share price in the next few days. View News Stories for Bellus Health.

Who are some of Bellus Health's key competitors?

What other stocks do shareholders of Bellus Health own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Bellus Health investors own include SandRidge Mississippian Trust II (SDR), Roku (ROKU), PhaseBio Pharmaceuticals (PHAS), Mid-Con Energy Partners (MCEP) and Lightbridge (LTBR).

Who are Bellus Health's key executives?

Bellus Health's management team includes the folowing people:
  • Mr. Roberto Bellini, Pres, CEO & Director (Age 39)
  • Mr. François Desjardins C.A., CPA, CPA, CA, VP of Fin. (Age 56)
  • Dr. Denis Garceau, Sr. VP of Drug Devel. (Age 62)
  • Mr. Tony Matzouranis, VP of Bus. Devel. (Age 46)
  • Dr. Catherine Bonuccelli, Chief Medical Officer

How do I buy shares of Bellus Health?

Shares of BLU can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Bellus Health's stock price today?

One share of BLU stock can currently be purchased for approximately $6.51.

How big of a company is Bellus Health?

Bellus Health has a market capitalization of $360.52 million. Bellus Health employs 10 workers across the globe.View Additional Information About Bellus Health.

What is Bellus Health's official website?

The official website for Bellus Health is http://www.bellushealth.com/.

How can I contact Bellus Health?

The company can be reached via phone at 450-680-4500.


MarketBeat Community Rating for Bellus Health (NYSE BLU)

Community Ranking:  3.2 out of 5 (star star star)
Outperform Votes:  7 (Vote Outperform)
Underperform Votes:  4 (Vote Underperform)
Total Votes:  11
MarketBeat's community ratings are surveys of what our community members think about Bellus Health and other stocks. Vote "Outperform" if you believe BLU will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BLU will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 10/14/2019 by MarketBeat.com Staff

Featured Article: Capital Gains Distribution

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel